BloFin to List ORC/USDT for Spot Trading (2026-6-26)

June 25, 2026 at 03:32 PM

Dear BloFin users,

To extend the range of trading options available on BloFin Spot and improve your trading experience, BloFin will list the $ORC (ORACLEEYES) token on our spot trading market.

The listing schedule is as follows:

About ORC (ORACLEEYES):

AI-powered personalized insights platform combining advanced neural networks with traditional wisdom frameworks to deliver instant destiny analysis and predictive guidance. Our proprietary AI engine processes birth data, temporal patterns, and life queries to generate hyper-personalized readings across 9 specialized categories.

X | Official Website

Explorer: 

https://bscscan.com/token/0xD9CDcE2Fb87552Ba1bF31EaBe0a8cE1f97951aE9

Please note:

To prevent potential losses, please ensure the selected chain or network on BloFin matches the one used for your withdrawal or deposit.

To align with market liquidity, BloFin may automatically adjust spot trading parameters. Please refer to the trading page for the most accurate information.

The listing schedule in the announcement is for reference only. The actual deposit/trading/withdrawal time shall prevail. For any questions, please contact our online support.

Further Reading:

To experience the innovative power of BloFin, please go to the BloFin website or download the app from the Apple App Store and Google Play Store to trade easily on the go.

Thanks for your support!  

BloFin Team

Jun 25, 2026

Find us on:

BloFin reserves the right, in its sole discretion, to amend or cancel this announcement at any time and for any reason without prior notice.

Risk Warning: Digital assets are highly speculative and subject to significant volatility. They may become illiquid at any time, and investors could lose the entire value of their investment. Before trading any digital asset, you should conduct your own research and assess your risk tolerance. BloFin is not liable for any losses you may incur from trading digital assets. This material should not be construed as financial advice. For more information, view our Terms of Use and Risk Warning.

Was this article helpful?